Matches in SemOpenAlex for { <https://semopenalex.org/work/W2243326503> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2243326503 abstract "Sorafenib (Nexavar), is a multikinase inhibitor, which has demonstrated both antiproliferative and antiangiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumoral cells (c-RAF [proto-oncogene serine/threonine-protein kinase], BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3) and in tumor vessels (c-RAF, vascular endothelial growth factor receptor [VEGFR]-2, VEGFR-3, and platelet-derived growth factor receptor β). Sorafenib was initially approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma. Experimental studies have demonstrated that sorafenib has both antiproliferative and antiangiogenic properties in vitro and in vivo, against thyroid cancer cells. Furthermore, several completed (or ongoing) studies have evaluated the long-term efficacy and tolerability of sorafenib in patients with papillary, follicular and medullary aggressive thyroid cancer. The results of the different studies showed good clinical responses and stabilization of the disease and suggested that sorafenib is a promising therapeutic option in patients with advanced thyroid cancer that is not responsive to traditional therapeutic strategies (such as radioiodine). Currently, USA Food and Drug Administration has approved the use of sorafenib for metastatic differentiated thyroid cancer." @default.
- W2243326503 created "2016-06-24" @default.
- W2243326503 creator A5002507768 @default.
- W2243326503 creator A5007252462 @default.
- W2243326503 creator A5010347660 @default.
- W2243326503 creator A5020994829 @default.
- W2243326503 creator A5028616896 @default.
- W2243326503 creator A5029781925 @default.
- W2243326503 creator A5038828476 @default.
- W2243326503 creator A5057155509 @default.
- W2243326503 creator A5082730409 @default.
- W2243326503 creator A5091108417 @default.
- W2243326503 date "2017-01-01" @default.
- W2243326503 modified "2023-09-27" @default.
- W2243326503 title "Aggressive thyroid cancer: targeted therapy with sorafenib" @default.
- W2243326503 doi "https://doi.org/10.23736/s0391-1977.16.02229-x" @default.
- W2243326503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26112458" @default.
- W2243326503 hasPublicationYear "2017" @default.
- W2243326503 type Work @default.
- W2243326503 sameAs 2243326503 @default.
- W2243326503 citedByCount "15" @default.
- W2243326503 countsByYear W22433265032016 @default.
- W2243326503 countsByYear W22433265032017 @default.
- W2243326503 countsByYear W22433265032018 @default.
- W2243326503 countsByYear W22433265032020 @default.
- W2243326503 countsByYear W22433265032021 @default.
- W2243326503 countsByYear W22433265032022 @default.
- W2243326503 countsByYear W22433265032023 @default.
- W2243326503 crossrefType "journal-article" @default.
- W2243326503 hasAuthorship W2243326503A5002507768 @default.
- W2243326503 hasAuthorship W2243326503A5007252462 @default.
- W2243326503 hasAuthorship W2243326503A5010347660 @default.
- W2243326503 hasAuthorship W2243326503A5020994829 @default.
- W2243326503 hasAuthorship W2243326503A5028616896 @default.
- W2243326503 hasAuthorship W2243326503A5029781925 @default.
- W2243326503 hasAuthorship W2243326503A5038828476 @default.
- W2243326503 hasAuthorship W2243326503A5057155509 @default.
- W2243326503 hasAuthorship W2243326503A5082730409 @default.
- W2243326503 hasAuthorship W2243326503A5091108417 @default.
- W2243326503 hasBestOaLocation W22433265032 @default.
- W2243326503 hasConcept C121608353 @default.
- W2243326503 hasConcept C126322002 @default.
- W2243326503 hasConcept C143998085 @default.
- W2243326503 hasConcept C2778019345 @default.
- W2243326503 hasConcept C2778695046 @default.
- W2243326503 hasConcept C2779341817 @default.
- W2243326503 hasConcept C2779761222 @default.
- W2243326503 hasConcept C2780120053 @default.
- W2243326503 hasConcept C2781230642 @default.
- W2243326503 hasConcept C2781461381 @default.
- W2243326503 hasConcept C2993294228 @default.
- W2243326503 hasConcept C502942594 @default.
- W2243326503 hasConcept C526584372 @default.
- W2243326503 hasConcept C71924100 @default.
- W2243326503 hasConceptScore W2243326503C121608353 @default.
- W2243326503 hasConceptScore W2243326503C126322002 @default.
- W2243326503 hasConceptScore W2243326503C143998085 @default.
- W2243326503 hasConceptScore W2243326503C2778019345 @default.
- W2243326503 hasConceptScore W2243326503C2778695046 @default.
- W2243326503 hasConceptScore W2243326503C2779341817 @default.
- W2243326503 hasConceptScore W2243326503C2779761222 @default.
- W2243326503 hasConceptScore W2243326503C2780120053 @default.
- W2243326503 hasConceptScore W2243326503C2781230642 @default.
- W2243326503 hasConceptScore W2243326503C2781461381 @default.
- W2243326503 hasConceptScore W2243326503C2993294228 @default.
- W2243326503 hasConceptScore W2243326503C502942594 @default.
- W2243326503 hasConceptScore W2243326503C526584372 @default.
- W2243326503 hasConceptScore W2243326503C71924100 @default.
- W2243326503 hasIssue "1" @default.
- W2243326503 hasLocation W22433265031 @default.
- W2243326503 hasLocation W22433265032 @default.
- W2243326503 hasLocation W22433265033 @default.
- W2243326503 hasOpenAccess W2243326503 @default.
- W2243326503 hasPrimaryLocation W22433265031 @default.
- W2243326503 hasRelatedWork W2019556233 @default.
- W2243326503 hasRelatedWork W2049084651 @default.
- W2243326503 hasRelatedWork W2069362902 @default.
- W2243326503 hasRelatedWork W2150001950 @default.
- W2243326503 hasRelatedWork W2167368296 @default.
- W2243326503 hasRelatedWork W2183602213 @default.
- W2243326503 hasRelatedWork W2243326503 @default.
- W2243326503 hasRelatedWork W4313431298 @default.
- W2243326503 hasRelatedWork W4315485237 @default.
- W2243326503 hasRelatedWork W44938027 @default.
- W2243326503 hasVolume "42" @default.
- W2243326503 isParatext "false" @default.
- W2243326503 isRetracted "false" @default.
- W2243326503 magId "2243326503" @default.
- W2243326503 workType "article" @default.